Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.

被引：0
|
作者：
Mustafayev, Fatma Nihan Akkoc [1 ]
Munsell, Mark [1 ]
Gutierrez-Barrera, Angelica M. [1 ]
Yam, Clinton [1 ]
Layman, Rachel M. [1 ]
Arun, Banu [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10587
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
    Sandhu, S. K.
    Omlin, A.
    Hylands, L.
    Miranda, S.
    Barber, L. J.
    Riisnaes, R.
    Reid, A. H.
    Attard, G.
    Chen, L.
    Kozarewa, I.
    Gevensleben, H.
    Campbell, J.
    Fenwick, K.
    Assiotis, I.
    Olmos, D.
    Yap, T. A.
    Fong, P.
    Tunariu, N.
    Koh, D.
    Molife, L. R.
    Kaye, S.
    Lord, C. J.
    Ashworth, A.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2013, 24 (05) : 1416 - 1418
  • [2] PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
    Taylor, Amelia M.
    Chan, David Lok Hang
    Tio, Martin
    Patil, Sujata M.
    Traina, Tiffany A.
    Robson, Mark E.
    Khasraw, Mustafa
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (04):
  • [3] Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
    Faraoni, Isabella
    Graziani, Grazia
    CANCERS, 2018, 10 (12):
  • [4] Inhibition of Poly(ADP-Ribose) Polymerase in BRCA Mutation Carriers REPLY
    Yap, Timothy A.
    Kaye, Stan B.
    de Bono, Johann S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (17) : 1707 - 1708
  • [5] Clinical Implications of Body Mass Index (BMI) in BRCA-associated Advanced Breast Cancer Patients Treated With PARP (Poly ADP-Ribose Polymerase) Inhibitors
    Mustafayev, Fatma Akkoc
    Munsell, Mark
    Layman, Rachel
    Yam, Clinton
    Barrera, Angelica Gutierrez
    Arun, Banu
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
    Liu, Chia-Hao
    Chang, Yi
    Wang, Peng-Hui
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2017, 56 (05): : 713 - 714
  • [7] Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
    Inderjeeth, Andrisha-Jade
    Topp, Monique
    Sanij, Elaine
    Castro, Elena
    Sandhu, Shahneen
    CANCERS, 2022, 14 (23)
  • [8] STATUS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS IN CLINICAL DEVELOPMENT
    Kummar, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 21 - 21
  • [9] Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer
    Garber, Haven R.
    Litton, Jennifer K.
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 247 - 255
  • [10] Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
    Tentori, L
    Portarena, I
    Graziani, G
    PHARMACOLOGICAL RESEARCH, 2002, 45 (02) : 73 - 85
12345